Shweta Bansal, Head of Department at Sir H.N. Reliance Foundation Hospital and Research Centre, shared a post on LinkedIn by Sir H.N. Reliance Foundation Hospital and Research Centre, adding:
“Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer — and one of the most curable.
With timely diagnosis, modern risk-adapted protocols, MRD (Minimal Residual Disease) monitoring, targeted therapies, and better supportive care, survival rates in children can reach 85–90% in well-managed centers.
I met Aman when he was 13, diagnosed with ALL in the middle of the COVID-19 pandemic. His journey was filled with challenges — infections, side effects, and hospital stays — but also moments of humour, resilience, and quiet strength.
Today, Aman is healthy, back at school, and thriving — a powerful reminder that while the road can be hard, the destination is worth it.
It’s also tells that for a child diagnosed with leukemia, the journey is tough — but today, the odds of winning are higher than ever.”
At Sir H. N. Reliance Foundation Hospital and Research Centre our pediatric hemato-oncology and BMT team is committed to giving every child this same fighting chance.”
Quoting Sir H. N. Reliance Foundation Hospital and Research Centre’s post below:
“Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer but with timely diagnosis, advanced treatment and expert care, survival rates are improving every day.
Dr. Shweta Bansal, HOD – Pediatric Hemato-oncology and BMT at Sir H. N. Reliance Foundation Hospital, leads a dedicated team offering precision treatment, bone marrow transplants and compassionate support for young patients and their families.
Together, we can raise awareness and give every child a fighting chance.”
More Posts Featuring Acute Lymphoblastic Leukemia.